Linear Monofunctional PEGs for PEGylation

JenKem PEGylation ReagentsJenKem Technology provides high quality linear reactive polyethylene glycol (PEG) products for PEGylation, with high purity, low polydispersity, and low to no diol content.

JenKem Technology’s linear monofunctional PEG derivatives have a reactive group at one end of the PEG polymer chain, while the other end is capped with a methoxy group or a sugar group. JenKem Technology provides linear methoxy PEG derivatives for amine PEGylation, thiol PEGylation, N-terminal PEGylation, and C-terminal PEGylation, for various applications [1]. Linear monofunctional PEG derivatives have the general structure: CAP―PEG―X, where X is the functional reactive group and CAP can be either a methoxy group (methoxy PEGs) or a targeting monosaccharide molecule (such as glucose-PEG and galactose-PEG).JenKem PEG Quality

Linear monofunctional PEG products with molecular weights and functional groups not listed in our online catalog may be available by custom synthesis.

Please inquire at about pricing and availability. For global distribution, please visit link. To order directly from JenKem Technology:

Linear NHS mPEGs with Cleavable Linker
M-PEG-SS ≥ 95% Methoxy PEG Succinimidyl Succinate is a degradable PEG linker reacting with the amino group of lysine(s) on proteins or other biologics, such as the amines on the active ingredients of Adagen®, Pegademase, PEG-adenosine deaminase, PEG aspargase, PEG-L-asparaginase, and related biosimilars, at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.[2,3]
M-PEG-SG ≥ 95% Methoxy PEG Succinimidyl Glutarate is a degradable PEG linker that reacts with the amino group of lysine(s) on proteins or other biologics at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.
Linear Monosaccharide NHS PEGs
GALA-PEG-NHS ≥ 90% Galactose PEG NHS reacts with amino group of lysine(s) at room temperature in under 1hr, at pH 7-8. The presence of the targeting galactose monosaccharide increases significantly the selectivity of the PEGylation reaction. [5]
GLUC-PEG-NHS ≥ 90% Glucose PEG NHS reacts with amine group of lysine(s) at room temperature in less than 1hr, at pH 7-8. The presence of the targeting sugar group (Glucose) increases significantly the selectivity of the PEGylation reaction. [5, 6]
Linear Methoxy NHS mPEGs with Stable Linker
M-PEG-SCM ≥ 95% Methoxy PEG Succinimidyl Carboxymethyl Ester reacts with the amine group of lysine(s) at room temperature in less than 1hr at pH 7-8. Shorter hydrolysis half life of M-PEG-SCM ensures maximum selectivity towards most sterically available amine groups. [7-9, 46, 47]
M-PEG-SPA ≥ 95% Methoxy PEG Succinimidyl Propionate (Methoxy PEG Succinimidyl Propanoate) reacts with the amine group of lysine(s, such as amines on the active ingredients of Somavert®, PEG-HGH antagonist, Pegvisomant, PEG growth hormone B2036, pegylated granulocyte colony stimulating factor MAXY-G34 ( PEG-CSF MAXY-G34), or Puricase PEG-uricase, Pegloticase, or Krystexxya®, and related biosimilars. [12]
M-PEG-SBA ≥ 95% Methoxy PEG Succinimidyl Butanoate reacts with the amine group of lysine(s), such as the amines on active ingredients of Mircera®, or Peg-epo biosimilars, at room temperature at pH 7-8. Methoxy PEG Succinimidyl Butanoate has a longer hydrolysis half-life compared with M-PEG-SCM.
M-PEG-SHA ≥ 95% Methoxy PEG Succinimidyl Hexanoate reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Hexanoate has a longer hydrolysis half-life compared with M-PEG-SCM and M-PEG-SBA. [10, 48, 49]
M-PEG-SSA ≥ 95% Methoxy PEG Succinimidyl Succinamide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Succinamide has a longer hydrolysis half-life compared with M-PEG-SCM.[11]
M-PEG-SGA ≥ 90% Methoxy PEG Succinimidyl Glutaramide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Glutaramide has a longer hydrolysis half-life compared with M-PEG-SCM. [12]
Linear Carbonate mPEGs
M-PEG-SC ≥ 95% Methoxy PEG Succinimidyl Carbonate reacts with the amino group of lysine(s) on proteins or other biologics, such as the amiens present on proteins for Peg-intron, PEG-IFN, Interferon alpha 2b, Pegintron®, Redipen, Sylatron and related biosimilars. Methoxy PEG Succinimidyl Carbonate has a longer hydrolysis half-life compared with M-PEG-SCM.[4]
M-PEG-NPC ≥ 90% Methoxy PEG Nitrophenyl Carbonate is reactive towards the the amino group of lysine(s) on proteins or other biologics, with a longer hydrolysis half-life compared with M-PEG-SCM.
Linear Carboxyl mPEGs
M-PEG-CM ≥ 95% Methoxy PEG Carboxyl (Methoxy PEG Acetic Acid, or M-PEG-COOH) is more stable than M-PEG-SCM.[16, 17, 50-52]
M-PEG-PA ≥ 95% Methoxy PEG Propionic Acid (Methoxy PEG Propanoic Acid) is more stable than M-PEG-SPA.[54]
M-PEG-BA ≥ 95% Methoxy PEG Butanoic Acid (Methoxy PEG Butyric Acid) is more stable than M-PEG-SBA.
M-PEG-HA ≥ 95% Methoxy PEG Hexanoic Acid  is more stable than M-PEG-SHA.
Linear Methoxy PEG Amine
M-PEG-NH2 ≥ 95% Methoxy PEG Amine. Attaches via stable linkages, such as amide, urethane, urea, secondary amine; the HCl salt form provides stability for the solid form of M-PEG-NH2 [18, 53, 55]
Linear Methoxy PEG Aldehyde
M-PEG-ALD ≥ 95% Methoxy PEG Aldehyde reacts with N-terminal amines, such as the N-terminal on proteins for Peg-filgastrim Peg-gsf, PEG-rhGCSF, Neulasta®, and related biosimilars, at pH 5-8 in the presence of a reducing reagent. [19-21]. Methoxy Propionaldehyde PEG with MW 20000 (M-ALD-20K) is utilized as a PEG raw material for pegfilgrastim PEGylated biosimilars [22].
Linear Methoxy Maleimide PEGs
M-PEG-MAL ≥ 95% Methoxy PEG Maleimide from JenKem Technology is a thiol reactive PEG derivative selective for thiol groups on cystein side chains. Methoxy PEG Maleimide undergoes thiol PEGylation reactions with thiol-containing molecules at pH 5.0-6.5.[23-25]
Linear Methoxy Vinylsulfone PEGs
M-PEG-VS ≥ 90% Methoxy PEG Vinylsulfone are high quality products for sulfhydryl PEGylation. Methoxy Vinylsulfone PEG products are special thiol PEGylation PEGs that react at high pH. [26]
Linear Methoxy Thiol PEGs
M-PEG-SH ≥ 95% Methoxy PEG Thiol is a high quality activated PEG product for thiol pegylation. Methoxy PEG Thiol PEGylates the thiol groups on cysteine side chains under mild reaction conditions.[27-30]
Biodegradable M-PEG Oligopeptides
M-PEG-GLU2 ≥95% Methoxy PEG Di-Glutamic Acid. Oligopeptide PEG for micelle formation used for drug encapsulation and drug delivery
M-PEG-GLU3 ≥90% Methoxy PEG Tri-Glutamic Acid. Oligopeptide PEG for micelle formation useful in drug encapsulation and drug delivery
PLL20K-G35-PEG2K ≥90%(Main peak wt%) PLL20K-G35-PEG2K, PEG-Poly(L-lysine), Poly(L-lysine), Graft Ratio 3.5, PLL MW 20000, PEG MW 2000 [31-35]
Click Chemistry PEGs
M-PEG-ALKYNE ≥90% Methoxy PEG Alkyne. Click chemistry PEG reagent for reaction with azide groups
M-PEG-AZIDE ≥90% Methoxy PEG Azide. The azide group may be reduced to amines by hydrogenolysis. Click PEG reagent for reaction with alkynes, simple reaction conditions, high selectivity, and rapid reaction with high yield. Water can be used as the reaction solvent. [36]
Other Special mPEG Products
M-PEG-HZ ≥95% Methoxy PEG Hydrazide reacts with aldehydes and ketones to give stable hydrazones in a single step; it can also react with activated carboxylic acids [37]
M-PEG-BIOTIN ≥90% Methoxy PEG Biotin. Avidin reactive PEG. Streptavidin reactive PEG. [38]
M-PEG-SLN ≥90% Methoxy PEG Silane for glass or silica surface modification and deactivation [39, 40]
M-PEG-ACLT ≥90% Methoxy PEG Acrylate reacts with sulfhydryl groups (Michael addition reaction). Used for Vinyl polymerization or co-polymerization [41]
M-PEG-PHOS ≥95% Methoxy PEG Phosphate. PEG reagent for surface modifications; increases water solubility. [42]
M-PEG-TA ≥90% Methoxy PEG Lipoic Acid. (mPEG Thioctic Acid). High affinity for metals, useful for gold nanoparticle surface modification. [43]
M-PEG-DSPE ≥95% Methoxy PEG DSPE mPEG phospholipid for liposome formation. [44, 45]
M-PEG-OA ≥90% Methoxy PEG OA mPEG Oleic Acid lipid for liposome formation.
Linear mPEG Hydroxyl Raw Materials
M-PEG MW 5000, 10kDa, 20kDa, 30kDa, 40kDa ≥95% ≤ 1.05-1.10
  1. Hutanu, D., et al., Recent Applications of Polyethylene Glycols (PEGs) and PEG Derivatives. Mod Chem appl 2014. 2(132).
  2. Mastorakos, P., et al., Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain. Small 2015. doi:10.1002/smll.201502554.
  3. Jain, S., et al., Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity, RSC Adv., 2014, 4, 29193-29201.
  4. Wan, X., et al., Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins, Process Biochemistry, 2017, 52:183-91.
  5. He, H., et al., Bolstering cholesteryl ester hydrolysis in liver: A hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis, Biomaterials, 2017, 130:1-3.
  6. Drappier, C., pH-Responsive Surface Shielding By Electrostatic Adsorption of PEG Segments With Anionic Chain End, Université Bordeaux 2013.
  7. Pan, H.M., et al., Engineering and Design of Polymeric Shells: Inwards Interweaving Polymers as Multilayer Nanofilm, Immobilization Matrix or Chromatography Resins. ACS Applied Materials & Interfaces. 2017.
  8. Liu, C., et al., iRGD-mediated core-shell nanoparticles loading carmustine and O6-benzylguanine for glioma therapy, Journal of Drug Targeting, 2017, 25(3):235-46.
  9. Gao, W., et al., Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer, International Journal of Nanomedicine, 2017, 12:1047.
  10. Mesken, J., et al., Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides–Cellular uptake and enhanced gene delivery, International journal of pharmaceutics, 2017, 522(1):198-209.
  11. Li, C., et al., Real-Time Monitoring Surface Chemistry-Dependent In Vivo Behaviors of Protein Nanocages via Encapsulating an NIR-II Ag2S Quantum Dot, ACS Nano, 2015, 9 (12), 12255-12263.
  12. Suarez, S.L., et al., Intramyocardial injection of hydrogel with high interstitial spread does not impact action potential propagation, Acta Biomaterialia, 2015, Volume 26, Pages 13-22.
  13. Pfister, D., et al., Integrated process for high conversion and high yield protein PEGylation, Biotechnol. Bioeng., 2016, doi:10.1002/bit.25932.
  14. Goffin V, et al., Pegvisomant Pfizer/Sensus. Curr Opin Investig Drugs. 2004;5:463–468.
  16. Lassenberger, A., et al., Individually stabilized, superparamagnetic nanoparticles with controlled shell and size leading to exceptional stealth properties and high relaxivities. ACS Applied Materials & Interfaces. 2017.
  17. Dai, L., et al., Self-assembled PEG–carboxymethylcellulose nanoparticles/α-cyclodextrin hydrogels for injectable and thermosensitive drug delivery. RSC Advances. 2017 ;7(5):2905-12.
  18. Huo, M., et al., Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment, Journal of Controlled Release, 2017, V. 245, P. 81-94.
  19. Mejia‐Manzano, L.A., et al., Optimized purification of mono‐PEGylated lysozyme by Heparin Affinity Chromatography using Response Surface Methodology, Journal of Chemical Technology and Biotechnology, 2017.
  20. Zhang, Y., et al., Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Scientific Reports. 2016; 6:21225.
  21. Mayolo‐Deloisa, K., et al., PEGylated protein separation using different hydrophobic interaction supports: Conventional and monolithic supports. Biotechnology progress, 2016.
  23. Chen, Y., et al., Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature, Biomaterials, 2017, V. 116, P. 57-68.
  24. Chang, X., et al., Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine, Vaccine, 2017, 35(13):1698-704.
  25. Wan, X., et al., Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins, Process Biochemistry, 2017, 52:183-91.
  26. Mahou, R., et al., Injectable and inherently vascularizing semi-interpenetrating polymer network for delivering cells to the subcutaneous space, Biomaterials, 2017.
  27. Su, B., et al., Effect of Retro‐Inverso Isomer of Bradykinin on Size‐Dependent Penetration of Blood–Brain Tumor Barrier, Small, 2018.
  28. Billingsley, M.M., et al., Antibody-nanoparticle conjugates to enhance the sensitivity of ELISA-based detection methods, PloS one, 2017, 12(5):e0177592.
  29. Li, S.S., et al., Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes, Scientific Reports, 2017, 7.
  30. Srivastava, I., et al., Surface chemistry of carbon nanoparticles functionally select their uptake in various stages of cancer cells, Nano Research, 2017:1-6.
  31. Schaedel, L., et al., Microtubules self-repair in response to mechanical stress, Nature Mater., 2015, 14(11):1156-63.
  32. Bhajun, R., et al., A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator, Scientific Reports, 2015, 5, Article number: 8336.
  33. Portran, D., Micropatterning Microtubules, Methods in Cell Biology, 2014, Academic Press, USA. 39-51.
  34. Boujemaa-Paterski, R., et al., Directed actin assembly and motility, Methods Enzymol, 2014, 540: 283-300.
  35. Vignaud, T., et al., Polyacrylamide hydrogel micropatterning. Methods Cell Biol, 2014, 120: 93-116.
  36. Li, J., et al., Smart Asymmetric Vesicles with Triggered Availability of Inner Cell-Penetrating Shells for Specific Intracellular Drug Delivery, ACS Applied Materials & Interfaces, 2017.
  37. Zhou, Z., et al., Comparison of Site-Specific PEGylations of the N-Terminus of Interferon Beta-1b: Selectivity, Efficiency, and in Vivo/Vitro Activity. Bioconjugate Chemistry, 2013. 25(1): p. 138-146.
  38. Wu, Y., et al., Fabrication of thermo-sensitive complex micelles for reversible cell targeting, Journal of Materials Science: Materials in Medicine, 2015, 26:255.
  39. Field, C.M., et al., Chapter 24 – Xenopus extract approaches to studying microtubule organization and signaling in cytokinesis, In: Arnaud Echard, Editor(s), Methods in Cell Biology, Academic Press, 2017, V. 137, P. 395-435.
  40. Huang, P., et al., Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced chemotherapeutic functionality, Biomaterials, 2017, V. 125, P. 23-37.
  41. Hu, Y., et al., Facile Construction of Mitochondria-Targeting Nanoparticles for Enhanced Phototherapeutic Effects, Biomaterials Science, 2017.
  42. Gonzalez-Villegas, J., et al., Poly (ethylene glycol)-modified zirconium phosphate nanoplatelets for improved doxorubicin delivery, Inorganica Chimica Acta, 2017.
  43. Limor Minai, et al., Optical Nanomanipulations of Malignant Cells: Controlled Cell Damage and Fusion, Small 2012, DOI: 10.1002/smll.201102304.
  44. Chen, Y., et al., An upconversion nanoparticle/Ru (ii) polypyridyl complex assembly for NIR-activated release of a DNA covalent-binding agent. RSC Advances. 2016, 6(28):23804-8.
  45. Farvadi, F., et al., Micellar stabilized single-walled carbon nanotubes for a pH-sensitive delivery of doxorubicin. Research in Pharmaceutical Sciences, 2014, 9(1):1-10.
  46. Wang, W., et al., Doxorubicin-loaded pH-sensitive polymeric blends for synergistic cancer treatment, RSC Adv., 2016, 6, 31167-31176.
  47. Yang, C., et al., Effects of PEGylation on biomimetic synthesis of magnetoferritin nanoparticles, Journal of Nanoparticle Research, 2017, 19(3):101.
  48. Look, L., et al., Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery, Molecular Pharmaceutics, 2015, 12 (9), 3202-3213.
  49. Gossmann, R., et al., Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS–PAGE and LC–MS, European Journal of Pharmaceutics and Biopharmaceutics, 2015, Volume 93, p. 80-87.
  50. Zhao, L., et al., An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration. Journal of Controlled Release. 2017.
  51. Abolmaali, S.S., et al., Chemically crosslinked nanogels of PEGylated poly ethyleneimine (l-histidine substituted) synthesized via metal ion coordinated self-assembly for delivery of methotrexate: Cytocompatibility, cellular delivery and antitumor activity in resistant cells. Materials Science and Engineering, 2016, C, 62, pp.897-907.
  52. Brinkman, A.M., et al., Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials. 2016, 101:20-31.
  53. Khandhar, A.P., et al.,. Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale. 2017.
  54. Zhang, C., et al., Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PloS one. 2012; 7(6): e39659.
  55. Chen, G., et al., Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. Journal of Controlled Release. 2017.

Founded in 2004 by recognized experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to on-site manufacturing from ethylene oxide, enabling facile traceability for GMP regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.